Drugs / Lymfactin®
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy2 trials | ||||||
| Phase 1 | NCT02994771 Comparator | Jun 2016 → Feb 2019 | lymphedema | Herantis Pharma Plc. | Terminated | No outcome recorded |
| Phase 2 | NCT03658967 Comparator | Jun 2018 → Dec 2019 | lymphedema | Herantis Pharma Plc. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Lymfactin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03658967 ↗ |
| Route | Other | “via perinodal injection” NCT02994771 ↗ |